HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Innovo Incontinence Device Goes OTC In US, Labeled To Be Worn For 30 Minutes

Executive Summary

Atlantic Therapeutics estimates that one in three women are incontinent, but 60% don’t ask their health care providers about treatment, a statistic that supports offering Innovo OTC less than two years after it launched Rx in the US.

You may also be interested in...

OTC Incontinence Device Ad Claims Sunk In UK, But US Label Claims Have FDA OK

UK ASA upholds complaints that questioned claims made in 2018 TV ads that Innovo was clinically proven to strengthen the pelvic floor and treat bladder weakness. In the US, however, claims Atlantic Therapeutics will use to promote OTC sales of Innovo were approved by FDA.

Global Device Approvals, Weekly Snapshot: Pelvic Floor Strengthener, Peripheral Stent

A snapshot of medical device approvals captured in Medtech Insight's Approvals Tracker. A muscle stimulation device to treat urinary incontinence passed US FDA's review, while a peripheral artery stent with a new delivery system gained European sign off.

Oxytrol For Women Exclusivity Ends Not With Competition, But Label Warning Change

Private labeler Perrigo has eyed launching a generic since FDA approved the 3.9mg oxybutynin transdermal as a first-in-class OTC in 2013. Currently, though, Perrigo says it is "not a big product" and is talking about other prescription OAB products that could be approved for OTC.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts